In vitro susceptibilities of enterococcal blood culture isolates from the Hamburg area to ten antibiotics

Chemotherapy

Volumn 46, Issue 2, 2000, Pages 104-110

  Elsner, Holger Andreas ^a,b   Sobottka, Ingo ^b   Feucht, Heinz Hubert ^b   Claussen, Matthias ^b   Kaulfers, Paul Michael ^b   Laufs, Rainer ^b   Mack, Dietrich ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antibiotics; Enterococcus faecalis; Enterococcus faecium; Fosfomycin; Quinupristin dalfopristin; Resistance; Vancomycin

Indexed keywords

AMPICILLIN; CLINDAMYCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FOSFOMYCIN; QUINUPRISTIN; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CONTROLLED STUDY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GERMANY; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 0033971691     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007263     Document Type: Article

References (25)

1. Murray BE: The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65.
2. Marcus N, Peled N, Yagupsky P: Rapid increase in the prevalence of antimicrobial drug resistance among enterococcal blood isolates in southern Isreael. Eur J Clin Microbiol Infect Dis 1997;16:913-915.
3. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, Moellering Jr R: Increasing resistance to β-lactam antibiotics among clinical isolates of Enterococcus faecium. A 22-year review at one institution. Antimicrob Agents Chemother 1991;35:2180-2184.
4. Devriese LA, Pot B, Collins MD: Phenotypic identification of the genus Enterococcus and differentiation of phylogenetically distinct enterococcal species and species groups. J Appl Bacteriol 1983;75: 399-408.
5. Facklam RR, Collins MD: Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989;27:731-734.
6. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow acrobically; approved standard M7-A3. NCCLS, 1993, Villanova, Pa.
7. Swenson JM, Ferraro MJ, Sahm DF, Clark NC, Culver DH, Tenover FC, and The National Committee for Clinical Laboratory Standards Study Group on Enterococci: Multi-laboratory evaluation of screening methods for detection of high-level aminoglycoside resistance in enterococci. J Clin Microbiol 1995;33: 3008-3018.
8. Swenson JM, Clark NC, Sahm DF, Ferraro MJ, Doern G, Hindler J, Jorgensen JH, Pfaller MA, Reller LB, Weinstein MP, Zabransky RJ, Tenover FC: Molecular characterization and multilaboratory evaluation of Enterococcus faecalis ATCC 51299 for quality control of screening tests for vancomycin and high-level aminoglycoside resistance in enterococci. J Clin Microbiol 1995; 33:3019-3021.
9. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB: The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997;24:584-602.
10. Jones RN, Sader HS, Erwin ME, Anderson SC, and the Enterococcus Study Group: Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical centers. Surveillance study in the United States. Diagn Microbiol Infect Dis 1995;21:85-93.
11. Vandamme P, Vercauteren E, Lammens C, Pensart N, Ieven M, Pot B, Leclercq R, Goossens H: Survey of enterococcal susceptibility patterns in Belgium. J Clin Microbiol 1996; 34:2572-2576.
12. Wallrauch C, Elsner E, Milatovic D, Cremer J, Braveny I: Antibiotikaresistenz der Enterokokken in Deutschland. Med Klin 1997;92: 464-468, 505.
13. Noskin GA, Peterson LR, Warren JR: Enterococcus faecium and Enterococcus faecalis bacteraemia: Acquisition and outcome. Clin Infect Dis 1995;20:296-301.
14. Elsner HA, Sobottka I, Feucht HH, Harps E, Haun C, Mack D, Ganschow R, Laufs R, Kaulfers PM: Nosocomial outbreak of vancomycin-resistant Enterococcus faecium at a German pediatric university hospital: Termination by infection control measures. submitted.
15. Centers for Disease Control and Prevention: Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-599.
16. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, Kusne S: Differences in outcomes for patients with bacteraemia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22: 663-670.
17. Stosor V, Peterson LR, Postelnick M, Noskin GA: Enterococcus faecium bacteremia: Does vancomycin resistance make a difference? Arch Intern Med 1998;158:522-527.
18. Barry AL, Fuchs PC, Brown SD: Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centers. J Antimicrob Chemother 1998;42:651-655.
19. Linden PK, Pasculle AW, McDevitt D, Kramer DJ: Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort. J Antimicrob Chemother 1997;39:(suppl A):145-151.
20. Barry AL, Fuchs PC, Brown SD: Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother 1997;39(suppl A):87-92.
21. Patel SS, Balfour JA, Bryson HM: Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997;53:637-656.
22. Andrews JM, Baquero F, Beltran JM, Canton E, Crokaert F, Gobernado M, Gomez-Luz R, Loza E, Navarro M, Olay T, Rodriguez A, Vicente MV, Wise R, Yourassowsky E: International collaborative study on standardization of bacterial sensitivities to fosfomycin. J Antimicrob Chemother 1983;12:357-361.
23. Fuchs PC, Barry AL, Brown SD: Susceptibility testing quality control studies with fosfomycin tromethamine. Eur J Clin Microbiol Infect Dis 1997;16:538-540.
24. Hamilton-Miller JMT: In vitro activity of fosfomycin against 'problem' gram-positive cocci. Microbios 1992;71:95-103.
25. Pestel M, Martin E, Aucouturier C, Lemeland JF, Caron F: In vitro interactions between different β-lactam antibiotics and fosfomycin against blood stream isolates of enterocci. Antimicrob Agents Chemother 1995;39:2341-2344.